Komori
Other Disclosures4891TMS Co.,Ltd.Pharmaceuticals

Progress toward conducting the early Phase II clinical trial of TMS-008 for acute kidney injury: Agreement signed with the first clinical trial site

For TMS-008's domestic early Phase II trial for acute kidney injury, an agreement was signed with the first clinical trial site to obtain IRB approval. This advanced the procedures toward starting case enrollment.

Worth reading
55In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
63
Planned number of cases (cases)
Wording
Conditional
How definitive the wording is.

Announced details

TMS-008
Applicable field (uses covered by this announcement)

Development of a therapeutic drug for patients at risk of acute kidney injury following cardiovascular surgery

Contract Date18 November 2026 (the date the completion of the contract signing was announced; the contract signing date itself: Not disclosed)
Relationship between the counterparty and the company
TMS Co.,Ltd.4891
Relationship with the Company

Contractual relationship for conducting TMS-008's clinical trial

CounterpartyFirst clinical trial site (name not disclosed)

Clinical trial site that obtained IRB approval. Location, representative, business activities, capital and year established: Not disclosed

Impact on Business Performance

There will be no impact on results for the fiscal year ending December 2026. The expenses for the current fiscal year required for this trial are included in the range of research and development expenses announced on 13 February 2026.

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Machado MN, et al. Rev Bras Cir Cardiovasc. 29: 299–307 (2014)

Announced details
ItemDetails
Names of Products / Services CoveredTMS-008
CounterpartyFirst clinical trial site (name not disclosed)
Counterparty overviewClinical trial site that obtained IRB approval. Location, representative, business activities, capital and year established: Not disclosed
Relationship with the CompanyContractual relationship for conducting TMS-008's clinical trial
Contract Date18 November 2026 (the date the completion of the contract signing was announced; the contract signing date itself: Not disclosed)
Applicable areaDevelopment of a therapeutic drug for patients at risk of acute kidney injury following cardiovascular surgery
Impact on Business PerformanceThere will be no impact on results for the fiscal year ending December 2026. The expenses for the current fiscal year required for this trial are included in the range of research and development expenses announced on 13 February 2026.
SourceMachado MN, et al. Rev Bras Cir Cardiovasc. 29: 299–307 (2014)
Items this document does not state (10)
Contract ValueOffering priceLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage history

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To advance the procedures toward starting case enrollment in this trial, with the aim of enrolling the first subject and completing enrollment at an early stage.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Progress toward conducting the early Phase II clinical trial of TMS-008 for acute kidney injury: Agreement signed with the first clinical trial site | TMS Co.,Ltd. (4891) timely disclosure | Komori